Market Research Logo

Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017

Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017

Summary


Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). There are a total of 163 products in development for this indication, by 118 companies and 25 academic institutions. Key companies operating in this pipeline space include Advaxis, F. Hoffmann-La Roche, GlaxoSmithKline, Kite Pharma, MedImmune and Pfizer.

The most prominent targets in the cervical cancer pipeline are HPV proteins there are a number of products in the pipeline targeting HPV protein E7 and HPV protein E6. Other common targets in the pipeline include vascular endothelial growth factor A and programmed cell death protein 1.

Vaginal cancer is a rare cancer that causes symptoms such as watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. There are a total of 6 products in development for this indication, by 6 companies. The companies operating in this pipeline space are ISA Pharmaceuticals, MedImmune, Ology Bioservices, Ono Pharmaceutical, Oryx GmbH & Co KG and Taiwan Liposome Company.

Finally, Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. There are a total of 5 products in development for this indication, by 5 companies. The five companies operating in this pipeline are Cutanea Life Sciences, ISA Pharmaceuticals, MedImmune, Ono Pharmaceutical and Oryx GmbH & Co KG

The report “Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017” provides an overview of the Lower Female Reproductive System Cancers pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Cervical Cancer, Vaginal Cancer and Vulvar Cancer, and features dormant and discontinued projects.

Scope

  • Which companies are the most active within the pipeline for genetic ophthalmological disorder therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of genetic ophthalmological disorders?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Lower Female Reproductive System Cancers Report Coverage
    • Cervical Cancer – Overview
    • Vaginal Cancer – Overview
    • Vulvar Cancer – Overview
  • Therapeutics Development
    • Cervical Cancer
      • Pipeline Overview
        • Table Figure 1: Number of Products under Development for Cervical Cancer
        • Table Number of Products under Development for Cervical Cancer
      • Pipeline by Companies
        • Table Figure 2: Number of Products under Development by Companies, Cervical Cancer
        • Table Number of Products under Development by Companies, Cervical Cancer
      • Pipeline by Universities/Institutes
        • Table Figure 3: Number of Products under Development by Universities/Institutes, Cervical Cancer
        • Table Number of Products under Development by Universities/Institutes, Cervical Cancer
      • Products under Development by Companies
        • Table Products under Development by Companies, Cervical Cancer
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Cervical Cancer
    • Vaginal Cancer
      • Pipeline Overview
        • Table Figure 4: Number of Products under Development for Vaginal Cancer
        • Table Number of Products under Development for Vaginal Cancer
      • Pipeline by Companies
        • Table Figure 5: Number of Products under Development by Companies, Vaginal Cancer
        • Table Number of Products under Development by Companies, Vaginal Cancer
      • Products under Development by Companies
        • Table Products under Development by Companies, Vaginal Cancer
    • Vulvar Cancer
      • Pipeline Overview
        • Table Figure 6: Number of Products under Development for Vulvar Cancer
        • Table Number of Products under Development for Vulvar Cancer
      • Pipeline by Companies
        • Table Figure 7: Number of Products under Development by Companies, Vulvar Cancer
        • Table Number of Products under Development by Companies, Vulvar Cancer
      • Products under Development by Companies
        • Table Products under Development by Companies, Vulvar Cancer
  • Therapeutics Assessment
    • Cervical Cancer
      • Assessment by Target
        • Table Figure 8: Number of Products by Top 10 Targets, Cervical Cancer
        • Table Figure 9: Number of Products by Stage and Top 10 Targets, Cervical Cancer
        • Table Number of Products by Stage and Target, Cervical Cancer
      • Assessment by Mechanism of Action
        • Table Figure 10: Number of Products by Top 10 Mechanism of Actions, Cervical Cancer
        • Table Figure 11: Number of Products by Stage and Top 10 Mechanism of Actions, Cervical Cancer
        • Table Number of Products by Stage and Mechanism of Action, Cervical Cancer
      • Assessment by Route of Administration
        • Table Figure 12: Number of Products by Routes of Administration, Cervical Cancer
        • Table Figure 13: Number of Products by Stage and Routes of Administration, Cervical Cancer
        • Table Number of Products by Stage and Route of Administration, Cervical Cancer
      • Assessment by Molecule Type
        • Table Figure 14: Number of Products by Top 10 Molecule Types, Cervical Cancer
        • Table Figure 15: Number of Products by Stage and Top 10 Molecule Types, Cervical Cancer
        • Table Number of Products by Stage and Molecule Type, Cervical Cancer
    • Vaginal Cancer
      • Assessment by Target
        • Table Figure 16: Number of Products by Targets, Vaginal Cancer
        • Table Figure 17: Number of Products by Stage and Targets, Vaginal Cancer
        • Table Number of Products by Stage and Target, Vaginal Cancer
      • Assessment by Mechanism of Action
        • Table Figure 18: Number of Products by Mechanism of Actions, Vaginal Cancer
        • Table Figure 19: Number of Products by Stage and Mechanism of Actions, Vaginal Cancer
        • Table Number of Products by Stage and Mechanism of Action, Vaginal Cancer
      • Assessment by Route of Administration
        • Table Figure 20: Number of Products by Routes of Administration, Vaginal Cancer
        • Table Figure 21: Number of Products by Stage and Routes of Administration, Vaginal Cancer
        • Table Number of Products by Stage and Route of Administration, Vaginal Cancer
      • Assessment by Molecule Type
        • Table Figure 22: Number of Products by Molecule Types, Vaginal Cancer
        • Table Figure 23: Number of Products by Stage and Molecule Types, Vaginal Cancer
        • Table Number of Products by Stage and Molecule Type, Vaginal Cancer
    • Vulvar Cancer
      • Assessment by Target
        • Table Figure 24: Number of Products by Targets, Vulvar Cancer
        • Table Figure 25: Number of Products by Stage and Targets, Vulvar Cancer
        • Table Number of Products by Stage and Target, Vulvar Cancer
      • Assessment by Mechanism of Action
        • Table Figure 26: Number of Products by Mechanism of Actions, Vulvar Cancer
        • Table Figure 27: Number of Products by Stage and Mechanism of Actions, Vulvar Cancer
        • Table Number of Products by Stage and Mechanism of Action, Vulvar Cancer
      • Assessment by Route of Administration
        • Table Figure 28: Number of Products by Routes of Administration, Vulvar Cancer
        • Table Figure 29: Number of Products by Stage and Routes of Administration, Vulvar Cancer
        • Table Number of Products by Stage and Route of Administration, Vulvar Cancer
      • Assessment by Molecule Type
        • Table Figure 30: Number of Products by Molecule Types, Vulvar Cancer
        • Table Figure 31: Number of Products by Stage and Molecule Types, Vulvar Cancer
        • Table Number of Products by Stage and Molecule Type, Vulvar Cancer
  • Companies Involved in Therapeutics Development
    • Cervical Cancer
      • Abion Inc
        • Table Cervical Cancer – Pipeline by Abion Inc
      • Abivax SA
        • Table Cervical Cancer – Pipeline by Abivax SA
      • Admedus Ltd
        • Table Cervical Cancer – Pipeline by Admedus Ltd
      • Advaxis Inc
        • Table Cervical Cancer – Pipeline by Advaxis Inc
      • Advenchen Laboratories LLC
        • Table Cervical Cancer – Pipeline by Advenchen Laboratories LLC
      • Agenus Inc
        • Table Cervical Cancer – Pipeline by Agenus Inc
      • Amgen Inc
        • Table Cervical Cancer – Pipeline by Amgen Inc
      • AntiCancer Inc
        • Table Cervical Cancer – Pipeline by AntiCancer Inc
      • Antigen Express Inc
        • Table Cervical Cancer – Pipeline by Antigen Express Inc
      • Arbor Vita Corp
        • Table Cervical Cancer – Pipeline by Arbor Vita Corp
      • ArQule Inc
        • Table Cervical Cancer – Pipeline by ArQule Inc
      • Asana BioSciences LLC
        • Table Cervical Cancer – Pipeline by Asana BioSciences LLC
      • AstraZeneca Plc
        • Table Cervical Cancer – Pipeline by AstraZeneca Plc
      • AVEO Pharmaceuticals Inc
        • Table Cervical Cancer – Pipeline by AVEO Pharmaceuticals Inc
      • Bayer AG
        • Table Cervical Cancer – Pipeline by Bayer AG
      • BeiGene Ltd
        • Table Cervical Cancer – Pipeline by BeiGene Ltd
      • Bioleaders Corp
        • Table Cervical Cancer – Pipeline by Bioleaders Corp
      • Biomics Biotechnologies Co Ltd
        • Table Cervical Cancer – Pipeline by Biomics Biotechnologies Co Ltd
      • Blirt SA
        • Table Cervical Cancer – Pipeline by Blirt SA
      • Boehringer Ingelheim GmbH
        • Table Cervical Cancer – Pipeline by Boehringer Ingelheim GmbH
      • Bristol-Myers Squibb Co
        • Table Cervical Cancer – Pipeline by Bristol-Myers Squibb Co
      • Cadila Healthcare Ltd
        • Table Cervical Cancer – Pipeline by Cadila Healthcare Ltd
      • Cancer Research Technology Ltd
        • Table Cervical Cancer – Pipeline by Cancer Research Technology Ltd
      • Celleron Therapeutics Ltd
        • Table Cervical Cancer – Pipeline by Celleron Therapeutics Ltd
      • Coherus BioSciences Inc
        • Table Cervical Cancer – Pipeline by Coherus BioSciences Inc
      • Critical Outcome Technologies Inc
        • Table Cervical Cancer – Pipeline by Critical Outcome Technologies Inc
      • Cytori Therapeutics Inc
        • Table Cervical Cancer – Pipeline by Cytori Therapeutics Inc
      • CZ BioMed Corp
        • Table Cervical Cancer – Pipeline by CZ BioMed Corp
      • DelMar Pharmaceuticals Inc
        • Table Cervical Cancer – Pipeline by DelMar Pharmaceuticals Inc
      • Dr. Reddy's Laboratories Ltd
        • Table Cervical Cancer – Pipeline by Dr. Reddy's Laboratories Ltd
      • Eisai Co Ltd
        • Table Cervical Cancer – Pipeline by Eisai Co Ltd
      • Etubics Corp
        • Table Cervical Cancer – Pipeline by Etubics Corp
      • Eureka Therapeutics Inc
        • Table Cervical Cancer – Pipeline by Eureka Therapeutics Inc
      • EyeGene Inc
        • Table Cervical Cancer – Pipeline by EyeGene Inc
      • F. Hoffmann-La Roche Ltd
        • Table Cervical Cancer – Pipeline by F. Hoffmann-La Roche Ltd
      • Formune SL
        • Table Cervical Cancer – Pipeline by Formune SL
      • GamaMabs Pharma SA
        • Table Cervical Cancer – Pipeline by GamaMabs Pharma SA
      • Gene Techno Science Co Ltd
        • Table Cervical Cancer – Pipeline by Gene Techno Science Co Ltd
      • Genentech Inc
        • Table Cervical Cancer – Pipeline by Genentech Inc
      • Genmab A/S
        • Table Cervical Cancer – Pipeline by Genmab A/S
      • Genor BioPharma Co Ltd
        • Table Cervical Cancer – Pipeline by Genor BioPharma Co Ltd
      • GlaxoSmithKline Plc
        • Table Cervical Cancer – Pipeline by GlaxoSmithKline Plc
      • Glycostem Therapeutics BV
        • Table Cervical Cancer – Pipeline by Glycostem Therapeutics BV
      • Glycotope GmbH
        • Table Cervical Cancer – Pipeline by Glycotope GmbH
      • Gradalis Inc
        • Table Cervical Cancer – Pipeline by Gradalis Inc
      • Immunomedics Inc
        • Table Cervical Cancer – Pipeline by Immunomedics Inc
      • Immunovaccine Inc
        • Table Cervical Cancer – Pipeline by Immunovaccine Inc
      • Innate Pharma SA
        • Table Cervical Cancer – Pipeline by Innate Pharma SA
      • Innovation Pharmaceuticals Inc
        • Table Cervical Cancer – Pipeline by Innovation Pharmaceuticals Inc
      • Iovance Biotherapeutics Inc
        • Table Cervical Cancer – Pipeline by Iovance Biotherapeutics Inc
      • ISA Pharmaceuticals BV
        • Table Cervical Cancer – Pipeline by ISA Pharmaceuticals BV
      • Johnson & Johnson
        • Table Cervical Cancer – Pipeline by Johnson & Johnson
      • Juno Therapeutics Inc
        • Table Cervical Cancer – Pipeline by Juno Therapeutics Inc
      • Kaketsuken
        • Table Cervical Cancer – Pipeline by Kaketsuken
      • Karyopharm Therapeutics Inc
        • Table Cervical Cancer – Pipeline by Karyopharm Therapeutics Inc
      • Kite Pharma Inc
        • Table Cervical Cancer – Pipeline by Kite Pharma Inc
      • LondonPharma Ltd
        • Table Cervical Cancer – Pipeline by LondonPharma Ltd
      • Mabion SA
        • Table Cervical Cancer – Pipeline by Mabion SA
      • MedImmune LLC
        • Table Cervical Cancer – Pipeline by MedImmune LLC
      • Merck & Co Inc
        • Table Cervical Cancer – Pipeline by Merck & Co Inc
      • Merck KGaA
        • Table Cervical Cancer – Pipeline by Merck KGaA
      • Mycenax Biotech Inc
        • Table Cervical Cancer – Pipeline by Mycenax Biotech Inc
      • Nektar Therapeutics
        • Table Cervical Cancer – Pipeline by Nektar Therapeutics
      • NeoImmuneTech Inc
        • Table Cervical Cancer – Pipeline by NeoImmuneTech Inc
      • Ology Bioservices Inc
        • Table Cervical Cancer – Pipeline by Ology Bioservices Inc
      • Oncobiologics Inc
        • Table Cervical Cancer – Pipeline by Oncobiologics Inc
      • Ono Pharmaceutical Co Ltd
        • Table Cervical Cancer – Pipeline by Ono Pharmaceutical Co Ltd
      • Oryx GmbH & Co KG
        • Table Cervical Cancer – Pipeline by Oryx GmbH & Co KG
      • PDS Biotechnology Corp
        • Table Cervical Cancer – Pipeline by PDS Biotechnology Corp
      • Pfizer Inc
        • Table Cervical Cancer – Pipeline by Pfizer Inc
      • Pharma Mar SA
        • Table Cervical Cancer – Pipeline by Pharma Mar SA
      • Psicofarma SA de CV
        • Table Cervical Cancer – Pipeline by Psicofarma SA de CV
      • Puma Biotechnology Inc
        • Table Cervical Cancer – Pipeline by Puma Biotechnology Inc
      • Regeneron Pharmaceuticals Inc
        • Table Cervical Cancer – Pipeline by Regeneron Pharmaceuticals Inc
      • Rexahn Pharmaceuticals Inc
        • Table Cervical Cancer – Pipeline by Rexahn Pharmaceuticals Inc
      • Richter Gedeon Nyrt
        • Table Cervical Cancer – Pipeline by Richter Gedeon Nyrt
      • Samyang Holdings Corp
        • Table Cervical Cancer – Pipeline by Samyang Holdings Corp
      • Sanofi
        • Table Cervical Cancer – Pipeline by Sanofi
      • Seattle Genetics Inc
        • Table Cervical Cancer – Pipeline by Seattle Genetics Inc
      • Selecta Biosciences Inc
        • Table Cervical Cancer – Pipeline by Selecta Biosciences Inc
      • Shantha Biotechnics Pvt Ltd
        • Table Cervical Cancer – Pipeline by Shantha Biotechnics Pvt Ltd
      • Sirnaomics Inc
        • Table Cervical Cancer – Pipeline by Sirnaomics Inc
      • Sun Pharma Advanced Research Company Ltd
        • Table Cervical Cancer – Pipeline by Sun Pharma Advanced Research Company Ltd
      • Tessa Therapeutics Pte Ltd
        • Table Cervical Cancer – Pipeline by Tessa Therapeutics Pte Ltd
      • Theralase Technologies Inc
        • Table Cervical Cancer – Pipeline by Theralase Technologies Inc
      • Theravectys SA
        • Table Cervical Cancer – Pipeline by Theravectys SA
      • THEVAX Genetics Vaccine USA Inc
        • Table Cervical Cancer – Pipeline by THEVAX Genetics Vaccine USA Inc
      • UbiVac LLC
        • Table Cervical Cancer – Pipeline by UbiVac LLC
      • Vectorite Biomedica Inc
        • Table Cervical Cancer – Pipeline by Vectorite Biomedica Inc
      • VLPbio
        • Table Cervical Cancer – Pipeline by VLPbio
      • Wellstat Biologics Corp
        • Table Cervical Cancer – Pipeline by Wellstat Biologics Corp
      • Zeria Pharmaceutical Co Ltd
        • Table Cervical Cancer – Pipeline by Zeria Pharmaceutical Co Ltd
    • Vaginal Cancer
      • ISA Pharmaceuticals BV
        • Table Vaginal Cancer – Pipeline by ISA Pharmaceuticals BV
      • MedImmune LLC
        • Table Vaginal Cancer – Pipeline by MedImmune LLC
      • Ology Bioservices Inc
        • Table Vaginal Cancer – Pipeline by Ology Bioservices Inc
      • Ono Pharmaceutical Co Ltd
        • Table Vaginal Cancer – Pipeline by Ono Pharmaceutical Co Ltd
      • Oryx GmbH & Co KG
        • Table Vaginal Cancer – Pipeline by Oryx GmbH & Co KG
      • Taiwan Liposome Company Ltd
        • Table Vaginal Cancer – Pipeline by Taiwan Liposome Company Ltd
    • Vulvar Cancer
      • Cutanea Life Sciences Inc
        • Table Vulvar Cancer – Pipeline by Cutanea Life Sciences Inc
      • ISA Pharmaceuticals BV
        • Table Vulvar Cancer – Pipeline by ISA Pharmaceuticals BV
      • MedImmune LLC
        • Table Vulvar Cancer – Pipeline by MedImmune LLC
      • Ono Pharmaceutical Co Ltd
        • Table Vulvar Cancer – Pipeline by Ono Pharmaceutical Co Ltd
      • Oryx GmbH & Co KG
        • Table Vulvar Cancer – Pipeline by Oryx GmbH & Co KG
  • Dormant Projects
    • Cervical Cancer
      • Table Cervical Cancer – Dormant Projects
    • Vaginal Cancer
      • Table Vaginal Cancer – Dormant Projects
    • Vulvar Cancer
      • Table Vulvar Cancer – Dormant Projects
  • Discontinued Products
    • Cervical Cancer
      • Table Cervical Cancer – Discontinued Products
  • Product Development Milestones
    • Cervical Cancer
      • Featured News & Press Releases
    • Vulvar Cancer
      • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report